Although previous studies have investigated the safety and efficacy characteristics of oral drugs in patients with premature ejaculation (PE), the available results remained inconsistent. Hence, this article was conducted to comprehensively compare the effectiveness of oral drugs and several relevant complications in patients with PE. Relevant researches were comprehensively searching from the databases PubMed, EMBASE, and Web of Science, up to May 1st, 2018. The pooled standard mean difference (SMD) or odds ratios (ORs) with 95% Credible interval (CrI) was respectively utilized to evaluate the safety and efficacy of oral drugs in PE. A total of 25 relevant research were ultimately included in this network meta-analysis. PE oral drugs mainly included serotonin reuptake inhibitors (SSRIs) and phosphodiesterase type 5 inhibitors (PDE5i). Our results successfully shed light on the efficacy differences of oral drugs for the treatment of PE. The cumulative rank probability of IELT at 4–6 weeks from best to worst was SSRIs + PDE5i, PDE5i, and other SSRIs alone. In addition, this meta-analysis also showed fluoxetine 20 mg, dapoxetine 60 mg, PDE5i, and SSRIs + PDE5i had a higher, whereas other SSRIs alone had a relatively lower incidence rate of clinically relevant complications. In summary, our results showed that the usage of PDE5i only or in combination with SSRIs might be stronger than SSRIs alone in the efficacy of PE oral drugs. Nevertheless, it also has a problem about the side effects of PDE5i including gastrointestinal or central nervous systems complications, which prevents it as the first-line treatment drug. Despite the development of some promising new therapeutic options, SSRIs remained as the first line of therapeutic PE oral drug through a synthetical consideration at present.

尽管先前的研究已经调查了口服药物在早泄（PE）患者中的安全性和疗效特征，但可用的结果仍然不一致。因此，本文旨在全面比较口服药物的有效性和PE患者的一些相关并发症。截至2018年5月1日，已从PubMed，EMBASE和Web of Science数据库中全面搜索了相关研究。分别使用具有95％可信区间（CrI）的合并标准均值差（SMD）或比值比（OR）来进行相关研究。评估口服药物在PE中的安全性和有效性。该网络荟萃分析最终包括总共25项相关研究。PE口服药物主要包括5-羟色胺再摄取抑制剂（SSRIs）和5型磷酸二酯酶抑制剂（PDE5i）。我们的结果成功阐明了口服药物治疗PE的功效差异。从最佳到最坏的4-6周内，IELT的累积排名概率仅为SSRI + PDE5i，PDE5i和其他SSRI。此外，该荟萃分析还显示，氟西汀20 mg，达泊西汀60 mg，PDE5i和SSRIs + PDE5i较高，而其他SSRIs仅具有相对较低的临床相关并发症发生率。总而言之，我们的结果表明，仅PDE5i或与SSRIs组合使用，在PE口服药物的功效上可能比单独使用SSRIs强。然而，它也存在关于PDE5i的副作用，包括胃肠道或中枢神经系统并发症，这使其无法作为一线治疗药物。尽管开发了一些有前途的新疗法，